期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿尔茨海默病创新药物的研发 被引量：2

Alzheimer's Disease and New Drug Research
下载PDF
导出
摘要 简述了阿尔茨海默病的分子病理学基础和近年有关药物的作用靶点和新药研究的进展。在研药物主要包括α-分泌酶激动剂、β-和γ-分泌酶抑制剂、促进Aβ的降解、针对Aβ的免疫疗法、胆碱脂酶抑制剂及N-甲基-D-门冬氨酸受体拮抗剂等。 The molecular pathogenesis of Alzheimer＇s disease （AD）, the therapeutic targets and the progress of the new drug research on AD are reviewed. Major therapeutic agents of AD include α-secretase agonists, β-secretase inhibitors, γ-secretase inhibitors, promotion on Aβ＇s degradation, Aβ immunotherapy, cholinesterase inhibitors and NMDA-receptor antagonists.
作者 刘佳 董文心
机构地区 上海医药工业研究院
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2007年第7期528-532,共5页 Chinese Journal of Pharmaceuticals
关键词 阿尔茨海默病 药物作用靶点 新药研发 综述 Alzheimer＇s disease therapeutic target new drug research review
分类号 R944.9 [医药卫生—药剂学]
  • 相关文献

参考文献33

  • 1陈新平,陈彪.阿尔茨海默病病因学及发病机制研究进展[J].中国现代神经疾病杂志,2005,5(3):152-155. 被引量：27
  • 2李嘉和,王颖实,尤海明.阿尔茨海默病新药开发现状[J].中国新药杂志,2003,12(10):794-803. 被引量：7
  • 3Silvestrelli G,Lanari A,Parnetti L,et al.Treatment of Alzheimer's disease:From pharmacology to a better understanding of disease pathophysiology[J].Mech Ageing Dev,2006,127 (2):148-157.
  • 4黄欣,柳川.以Aβ为靶标治疗阿尔茨海默病的研究进展[J].生物技术通讯,2005,16(1):87-89. 被引量：5
  • 5徐宝钢,吴逊.淀粉样前体蛋白在阿尔茨海默病分子生物学和临床医学中的研究进展[J].中国医学科学院学报,2004,26(2):201-209. 被引量：9
  • 6Yang P,Baker KA,Hagg T.The ADAMs family:coordinators of nervous system development,plasticity and repair[J].Prog Neurobiol,2006,79(2):73-94.
  • 7Colciaghi F,Borroni B,Zimmermann M,et al.Amyloid precursor protein metabolism is regulated toward alphasecretase pathway by Ginkgo biloba extracts[J].Neurobiol Dis,2004,16 (2):454-460.
  • 8Harada H,Tamaoka A,Ishii K,et al.Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains[J].Neurosci Res,2006,54 (1):24-29.
  • 9Bodendorf U,Danner S,Fischer F,et al.Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid[J].J Neurochem,2002,80 (5):799-806.
  • 10Ghosh AK,Bilcer G,Harwood C,et al.Structure-based design:potent inhibitors of human brain memapsin 2 (betasecretase)[J].J Med Chem,2001,44 (18):2865-2868.Hu J,Cwi CL,Smiley DL,et al.Design and synthesis of

二级参考文献148

  • 1[1]Bird TD. Genetic factors in Alzheimer's disease. N Engl J Med,2005, 352:862-864.
  • 2[2]Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med, 2003, 348:1356-1364.
  • 3[3]Torreilles F, Touchon J. Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer's disease. Prog Neurobiol, 2002,66:191-203.
  • 4[4]De Strooper B. Aph-l, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron, 2003, 38:9-12.
  • 5[5]Nyabi O, Bentahir M, Horre K, et al. Presenilins mutated at Asp-257 or Asp-385 restore Pen-2 expression and Nicastrin glycosylation but remain catalytically inactive in the absence of wild type Presenilin. J Biol Chem, 2003, 278:43430-43436.
  • 6[6]Qyang Y, Chambers SM, Wang P, et al. Myeloproliferative disease in mice with reduced presenilin gene dosage: effect of gamma-secretase blockage. Biochemistry, 2004, 43:5352-5359.
  • 7[7]Marjaux E, Hartmann D, De Strooper B. Presenilins in memory,Alzheimer's disease, and therapy. Neuron, 2004, 42:189-192.
  • 8[8]Kamboh MI. Molecular genetics of late-onset Alzheimer's disease.Ann Hum Genet, 2004, 68:381-404.
  • 9[9]Barghorn S, Zheng-Fischhofer Q, Ackmann M, et al. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry, 2000, 39:11714-11721.
  • 10[10]Bertram L, Hiltunen M, Parkinson M, et al. Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med, 2005, 352:884-894.

共引文献46

同被引文献6

引证文献2

中国医药工业杂志
2007年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部